Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB502232860

Publication Date:

February 6, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years.
Highlights
The global Acute Myeloid Leukemia Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Geographically, acute myeloid leukemia therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held substantial share of the acute myeloid leukemia therapeutics market owing to prominent growth factors including rising incidences of acute myeloid leukemia and increasing geriatric population. Furthermore, advanced healthcare infrastructure, rising need of targeted therapies, huge investment in the development of pipeline drugs, and awareness amongst the population base induced market growth in this region. Asia Pacific is expected to be the fastest growing region over the forecast period owing to growth factors such as rising investments, rising disposable incomes, increasing cancer awareness, and improving healthcare infrastructure. Additionally, increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also anticipated to propel the demand for the acute myeloid leukemia therapeutics market in this region.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Therapeutics.
The Acute Myeloid Leukemia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Acute Myeloid Leukemia Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline
Segment by Type
Pipeline Drugs
Chemotherapy Drugs
Chemotherapy Regimens
Segment by Application
Hospitals
Clinics
麻豆原创 Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Pipeline Drugs
1.2.3 Chemotherapy Drugs
1.2.4 Chemotherapy Regimens
1.3 麻豆原创 by Application
1.3.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 麻豆原创 Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Acute Myeloid Leukemia Therapeutics Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Myeloid Leukemia Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Acute Myeloid Leukemia Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Acute Myeloid Leukemia Therapeutics 麻豆原创 Dynamics
2.3.1 Acute Myeloid Leukemia Therapeutics Industry Trends
2.3.2 Acute Myeloid Leukemia Therapeutics 麻豆原创 Drivers
2.3.3 Acute Myeloid Leukemia Therapeutics 麻豆原创 Challenges
2.3.4 Acute Myeloid Leukemia Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia Therapeutics Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Acute Myeloid Leukemia Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Myeloid Leukemia Therapeutics Revenue
3.4 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Therapeutics Revenue in 2022
3.5 Acute Myeloid Leukemia Therapeutics Key Players Head office and Area Served
3.6 Key Players Acute Myeloid Leukemia Therapeutics Product Solution and Service
3.7 Date of Enter into Acute Myeloid Leukemia Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia Therapeutics Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Acute Myeloid Leukemia Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Acute Myeloid Leukemia Therapeutics Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Acute Myeloid Leukemia Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ambit Biosciences Corporation
11.1.1 Ambit Biosciences Corporation Company Detail
11.1.2 Ambit Biosciences Corporation Business Overview
11.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Therapeutics Introduction
11.1.4 Ambit Biosciences Corporation Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.1.5 Ambit Biosciences Corporation Recent Development
11.2 Genzyme Corporation Celgene Corporation
11.2.1 Genzyme Corporation Celgene Corporation Company Detail
11.2.2 Genzyme Corporation Celgene Corporation Business Overview
11.2.3 Genzyme Corporation Celgene Corporation Acute Myeloid Leukemia Therapeutics Introduction
11.2.4 Genzyme Corporation Celgene Corporation Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.2.5 Genzyme Corporation Celgene Corporation Recent Development
11.3 Clavis Pharma ASA
11.3.1 Clavis Pharma ASA Company Detail
11.3.2 Clavis Pharma ASA Business Overview
11.3.3 Clavis Pharma ASA Acute Myeloid Leukemia Therapeutics Introduction
11.3.4 Clavis Pharma ASA Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.3.5 Clavis Pharma ASA Recent Development
11.4 Sunesis Pharmaceuticals
11.4.1 Sunesis Pharmaceuticals Company Detail
11.4.2 Sunesis Pharmaceuticals Business Overview
11.4.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Therapeutics Introduction
11.4.4 Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.4.5 Sunesis Pharmaceuticals Recent Development
11.5 Cephalon
11.5.1 Cephalon Company Detail
11.5.2 Cephalon Business Overview
11.5.3 Cephalon Acute Myeloid Leukemia Therapeutics Introduction
11.5.4 Cephalon Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.5.5 Cephalon Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Acute Myeloid Leukemia Therapeutics Introduction
11.6.4 Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Novartis International AG
11.7.1 Novartis International AG Company Detail
11.7.2 Novartis International AG Business Overview
11.7.3 Novartis International AG Acute Myeloid Leukemia Therapeutics Introduction
11.7.4 Novartis International AG Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.7.5 Novartis International AG Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Acute Myeloid Leukemia Therapeutics Introduction
11.8.4 GlaxoSmithKline Revenue in Acute Myeloid Leukemia Therapeutics Business (2018-2023)
11.8.5 GlaxoSmithKline Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.